Akamis Bio

Akamis Bio is a private, clinical-stage biotech targeting the significant unmet need in colorectal cancer with its proprietary T-SIGn® oncolytic immunotherapy platform. The company's lead program, NG-350A, is in a Phase 1b trial (FORTRESS) for mismatch repair-proficient locally advanced rectal cancer, with initial data expected at AACR 2026. With a focused pipeline, experienced leadership, and a capital-efficient, entrepreneurial ethos, Akamis aims to transform treatment paradigms by potentially reducing the need for invasive surgeries and improving patient quality of life.

Tumor-Specific Immuno-Gene (T-SIGn®) platform: a systemically administered, replication-competent oncolytic adenovirus platform optimized to target epithelial solid tumors. It delivers immunomodulatory transgene payloads directly to the tumor microenvironment to stimulate anti-tumor immunity.

Competes in the oncolytic virus space with companies like Amgen (Imlygic) and others in development, and more broadly with all immuno-oncology and targeted therapy developers in colorectal cancer. Differentiation is sought through systemic administration, tumor-specific targeting, and payload delivery aimed at the pMMR population.